

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/614,923	07/08/2003	Marie-Claire Grosjean-Cournoyer	A34658-PCT-USA-I (072667.	3094
21003 75	590 12/01/2006		EXAMINER.	
BAKER & BO	OTTS L.L.P.		SCHLAPKOHL, WALTER	
30 ROCKEFEI	LER PLAZA			
44TH FLOOR			ART UNIT	PAPER NUMBER
NEW YORK,	NY 10112-4498	•	1636	

DATE MAILED: 12/01/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	·				
Office Action Commence	10/614,923	GROSJEAN-COURNOYER ET AL.					
Office Action Summary	Examiner	Art Unit					
	Walter Schlapkohl	1636	waf				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	S				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this commun D (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 11 Se	entember 2006						
	action is non-final.						
· ·							
,—	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
olocco in accordance with the placetee united.	purto Quayro, 1000 0.D. 11, 10						
Disposition of Claims	•						
4) Claim(s) <u>20-35</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdraw	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)⊠ Claim(s) <u>30-35</u> is/are allowed.							
(a) Claim(s) <u>20,21,25-27 and 29</u> is/are rejected.							
7) Claim(s) <u>22-24 and 28</u> is/are objected to.							
8) Claim(s) are subject to restriction and/or	r election requirement						
are easyest to recurrence and a							
Application Papers							
9) The specification is objected to by the Examine	r.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correct	=		121(d).				
11) The oath or declaration is objected to by the Ex							
•							
Priority under 35 U.S.C. § 119	•						
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents)-(d) or (f).					
Certified copies of the priority documents	s have been received in Applicati	on No					
Copies of the certified copies of the prior	ity documents have been receive	ed in this National Stag	е				
application from the International Bureau	ı (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list	of the certified copies not receive	ed.					
Attachment(s)	_						
1) Notice of References Cited (PTO-892)	4) Interview Summary						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	Paper No(s)/Mail D 5) Notice of Informal F						
Paper No(s)/Mail Date	6) Other:						

DETAILED ACTION

Page 2

Receipt is acknowledged of the papers filed 9/11/2006 in which claims 20 and 30 were amended. Claims 20-35 are pending and under examination in the instant Office action.

Any rejection made in the previous Office action not set forth herein is hereby WITHDRAWN.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/11/2006 has been entered.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary.

Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

This is a new rejection not necessitated by Applicant's amendment.

Claims 20-21, 25-27 and 29 are rejected under 35 U.S.C.

103(a) as being unpatentable over Daboussi (*J. Genet.* **75**(3):325-339, 1996; of record; IDS Ref. 10) in view of Migheli et al (*Genetics* **151**:1005-1013, 1999).

Daboussi teaches a method for identifying a gene associated with a detectable phenotype in a fungus, comprising: (a) transforming the fungus with a polynucleotide comprising a marker gene (niaD) which would otherwise be transcriptionally active in the fungus but which has been inactivated by the insertion of an Impala transposon, said marker gene comprising, in the direction of transcription, a promoter regulatory sequence of the niaD gene under conditions in which transposase is expressed, which allow the excision of the Impala transposon from said marker gene and its reinsertion into the genome of the fungus; (b) selecting at least one insertion mutant with said detectable phenotype: and (c) isolating the gene into which or close to which the Impala tansposon has inserted (see entire document, especially pages 334-335, section 7.2 "Development of a gene tagging system" and Figure 4). Although Daboussi does not explicitly teach such a method wherein the niaD gene promoter is more than 0.4 kb long, such a limitation is inherent because the reference teaches the use of the (entire) niaD gene and not, e.g., the use of a niaD gene with a truncated promoter.

Daboussi does not teach such a method wherein the niaD gene is from Aspergillus nidulans or wherein the Impala transposon carries an additional marker gene.

Page 5

Art Unit: 1636

Migheli et al teach a method for gene tagging comprising the use of a Fot1 transposon which has been inserted into the niaD gene of Aspergillus nidulans. (see entire document, especially paragraph bridging pages 1007-1008, as well as Figure 1 on page 1008). Migheli et al teach that the use of niaD from A. nidulans functions as a marker in nia recipient strains (ibid). Migheli et al also teach such a method wherein the transposon used for the tagging carries an hph-resistance marker (see, e.g., page 1006, paragraph bridging first and second columns, and page 1012, first paragraph, last sentence). Migheli et al teach that this resistance marker could be used in a tagging system which would provide the advantage of a two component system as was previously described for plants (see page 1012, first paragraph, last sentence). Migheli et al also teach that a marker placed in the transposon can be used for testing of transformants for either frameshift, deletion or other disruptions of the transposase associated with the transposon (see paragraph bridging first and second columns on page 1008).

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to use the niaD gene of Aspergillus nidulans as taught by Migheli in a method of gene tagging wherein the niaD gene is interrupted by an impala

transposon as taught by Daboussi because both Daboussi and Migheli et al teach methods of gene tagging with the use of niaD genes and Migehli et al teach such a method specifically using the niaD gene of Aspergillus nidulans. It would also have been obvious for one of ordinary skill in the art to use an impala transposon which carries an additional marker as taught by the combined references because Migheli et al teach that such an additional marker can be used to indicate whether or not the transposase has undergone mutation post-transformation.

One of ordinary skill in the art would have been motivated to use the A. nidulans niaD gene as taught by Migheli et al in the method taught by Daboussi because Migheli et al teach that such a gene from A. nidulans is a functional marker within a nia fungal strain. One of ordinary skill in the art would have been motivated to place an additional marker within the transposon not only for the added benefit of testing whether the transposase had undergone frameshift, deletion or disruption as taught by Migheli et al, but also because such a marker, in the context of a gene tagging system, would provide the basis of a two-component system as had already been described in plants.

Based upon the teachings of the cited references, the high skill of one of ordinary skill in the art, and absent evidence to the contrary, there would have been a reasonable expectation

of success to result when combining the method of gene identification comprising the use of a niaD gene as taught by Daboussi with the teachings of Migheli et al.

Allowable Subject Matter

Claims 22-24 and 28 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claims 30-35 are allowed.

Conclusion

Certain papers related to this application may be submitted to the Art Unit 1636 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone number for the Group is (571) 273-8300. Note: If Applicant does submit a paper by fax, the original signed copy should be retained by Applicant or Applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent applications to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at (800) 786-9199.

Application/Control Number: 10/614,923 Page 9

Art Unit: 1636

Any inquiry concerning rejections or objections in this communication or earlier communications from the examiner should be directed to Walter Schlapkohl whose telephone number is (571) 272-4439. The examiner can normally be reached on Monday through Thursday from 8:30 AM to 6:00 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel can be reached at (571) 272-0781.

Walter A. Schlapkohl, Ph.D. Patent Examiner
Art Unit 1636

November 15, 2006

NANCY VOGEL PRIMARY EXAMINER